ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

Final results from two large phase III trials confirm that the drug-antibody conjugate trastuzumab emtansine improves overall survival over other treatment options in patients with previously treated HER2-positive metastatic breast cancer.

Treatment with metformin may improve outcomes in patients with HER2–positive primary breast cancer and diabetes, according to an analysis of the phase III ALTTO trial.

The 2013 ASCO/CAP updates to HER2 testing guidelines did not result in changes to the rate of HER2 positivity among breast cancer patients.

Trastuzumab plus low-dose radiotherapy does not have a significant effect on left ventricular ejection fraction changes in HER2-positive breast cancer.

Administration of dexrazoxane along with adjuvant chemotherapy was cardioprotective in patients with HER2-positive breast cancer treated with chemotherapy followed by 1 year of trastuzumab maintenance therapy.

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.